
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GILD | NASDAQ | USD | Real-time | |
GILD | Mexico | MXN | Delayed | |
GGILD | Milan | EUR | Real-time | |
GILD | Xetra | EUR | Delayed | |
GILD | Frankfurt | EUR | Delayed | |
GILD | TradeGate | EUR | Delayed | |
GILDCL | Santiago | CLP | Delayed | |
GILD | Santiago | USD | Delayed | |
GILD | Buenos Aires | ARS | Delayed | |
GILD | Vienna | EUR | Delayed | |
GILD-RM | Moscow | RUB | Real-time |
The FDA has lifted the clinical hold placed on Gilead Sciences Inc's (NASDAQ: GILD) Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure...
HOOKIPA Pharma Inc. (HOOK) today reported financial results and business highlights for the first quarter of 2022.“We observed strong external validation of our novel arenaviral platform in the first...
Friday's top analyst upgrades and downgrades included AppLovin, BioCryst Pharmaceuticals, Boeing, CF Industries, Coupa Software, Crocs, Dutch Bros, DigitalOcean, Gilead Sciences, IBM, International...
Monday's top analyst upgrades and downgrades included Amazon.com, Apple, Caterpillar, Comcast, Comerica, Gilead Sciences, Intel, Lululemon Athletica and McDonald's.
RBC Capital Market views Gilead Sciences Inc's (NASDAQ: GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal...
Gilead Sciences (NASDAQ:GILD) reported its Q1 results, with EPS of $2.12 coming in better than the consensus estimate of $1.81. Revenue grew 3% year-over-year to $6.6 billion, compared to the...
By Deena Beasley (Reuters) – Gilead Sciences Inc on Thursday said its first-quarter revenue rose 3%, helped by increased sales of HIV drug Biktarvy and COVID-19 antiviral drug Veklury.
Gilead Sciences (NASDAQ:GILD) reported Q1 EPS of $2.12, $0.31 better than the analyst estimate of $1.81. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.28...
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings per share of $2.12 on...
How Gilead is positioning Veklury vs. such COVID antivirals as Paxlovid
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review